Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Assoc. Prof. Folkert Asselbergs,
View the Slides from this session in ESC Congress 365
This symposium clearly illustrated that pharmacogenetics is not an obscure hobby of basic scientists, but will be applicable in clinical practice in the near future.
Dr. Munir Pirmohamed (Liverpool, GB) and Dr Anke Hilse Maitland-van der Zee (Utrecht, NL) discussed whether dosing of oral anticoagulants needs to be guided by pharmacogenetics. The jury is still out, but a genotype-guided loading dose of anticoagulants seems beneficial, especially when genotyping costs keep decreasing.
Another clinical application is the genetic background of statin side effects as discussed by Dr. Mikko Niemi from (Helsinki, FL). Several genetic factors have been identified that increases the toxicity of certain statins, one variant increases the risk more than threefold. Dr. Niemi proposed creating a guideline for statin prescription based on genotype information. Availability of genetic information in patients using statins would help to prevent severe drug reactions.
Finally, Dr Elijah Behr ( London, GB) updated the audience regarding genetics of QT prolongation and torsades de pointes by drug use. Some interesting variants, such as NOS1AP were identified but large sample sizes are needed to fully understand the underlying genetic background responsible for QT prolongation.
In conclusion, pharmacogenetics is an exciting fast-moving field that cannot be ignored anymore by the practicing clinician. It will only be matter of time before patients provide you with their genetic data to interpret.
Pharmacogenetics: ready for clinical practice?, Science in Practice from early detection to guided treatment
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved